Panacos is engaged in the discovery, development and commercialization of small molecule drugs to treat or prevent
serious infectious disease. The Company has an expanding pipeline of promising anti-infective drug candidates for
major markets with significant, unmet medical needs. The Company's lead antiviral product is bevirimat (PA-457),
the first in a new class of drugs to treat HIV infection discovered by Panacos scientists currently in Phase 2
clinical trials.
An animation showing bevirimat's mechanism of action can be found here.
